References for Specific Topics
Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical guidelines. Pharmacol Therapeutics. 2011;89:924–927.
Bennett MJ. Newborn screening for metabolic diseases: saving children’s lives and improving outcomes. Clin Biochem. 2014;47(9):693–694.
Dorschner MO, Amendola LM, Turner EH, et al. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum Genet. 2013;93:631–640.
Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543–1546.
Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med. 2009;361:245–254.
Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet Med. 2012;14:399–404.
Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges and opportunities. Sci Transl Med. 2013;5:189sr4.
Topol EJ. Individualized medicine from prewomb to tomb. Cell. 2014;157:241–253.
Urban TJ, Goldstein DB. Pharmacogenetics at 50: genomic personalization comes of age. Sci Transl Med. 2014;6:220ps1.
